Introducing a clinical trial for previously vaccinated adults Including those who are at increased risk of severe illness from COVID-19
Flu virus changes every year, and that's why yearly vaccination is the most effective way to help prevent flu and its complications.
In this study, we will be working together to see if an investigational medicine is safe to use, and whether it can help people with overweight or obesity to lose weight and manage weight-related conditions. The investigational medicine is a monthly injection that is given subcutaneously (under the skin). Increasing physical activity and reducing the number of calories eaten does not necessarily lead to a reduction in weight for all individuals. As obesity continues to increase, this is a concern, as some diseases are known to occur more often in people with overweight or obesity.
Participate in a Research Study on Satiety: You may qualify for a clinical trial evaluating the effects of a natural prebiotic (Arrabina®P) on appetite, mood, sleep, and more!
The Duo P201 Trial Part 2 will evaluate the safety and immune response of 2 batches of an investigational combination vaccine aimed at preventing both seasonal flu and COVID-19 infections in adults 50 to 64 years of age.
A Phase 2 Randomized, Placebo-Controlled, Double-Blind, Parallel-group Study to Evaluate the Efficacy and Safety of study drug as Adjunctive Therapy in Participants with Mild to Moderate Alzheimer’s Disease Dementia.
Can I join this study?
Yes, you may be able to join the research study if you:
Has mild to moderate AD dementia (ie, Stage 4 or Stage 5 AD) based on the Alzheimer’s Association Revised Criteria for Diagnosis and Staging of Alzheimer’s Disease.
Is an individual of any sex/gender, from 55 to 90 years of age inclusive, at the time of providing the informed consent as applicable.
The participant (or legally acceptable representative) has provided documented informed consent for the study.
Study Duration:
Study will require approximately 30 months from the time the first participant (or their legally acceptable representative) provides documented informed consent until the last participant’s last study-related contact.
More information:
Indago Research & Health Center, Inc.
Call: 305-825-6588
The GN02 study is a new clinical research study from Eli Lilly and Company. GN02 is a weight management study. It will test if an investigational medicine can safely reduce body weight in people with type 2 diabetes and obesity or overweight when compared to placebo.
Investigational medicine means it is still being tested in clinical research studies. A placebo looks the same as an investigational medicine but does not have any real medicine in it.
Can I join this study?
Yes, you may be able to join the study if you:
- are aged 18 to 75 years
- cannot become pregnant
- have type 2 diabetes that you treated with diet and exercise alone or with a stable dose of metformin.
- have not taken insulin in the past year, and
- have a BMI of 27kg/m 2 or more
BMI stands for body mass index. It is a number that compares a person’s weight to their height. It can be used to tell if a person may be at risk of some health conditions.
For more information: 786-772-0510
Learn more about Pfizer and BioNTech’s clinical trial for an investigational COVID-19 and flu vaccine using mRNA technology
Researchers are testing an investigational medicine for COVID-19. They want to know how well it may work and if it is safe in adults with COVID-19 who are at a higher risk for severe illness from COVID-19.
One and done: Help make dual protection against COVID-19 and flu possible with a combination vaccine
Help make dual protection against COVID-19 and flu possible with a combination vaccine
Indago delivers community-based services for Miami and neighboring areas, driving advances in investigational research for new and improved drugs.
Working Hours
Monday-Friday 8:00 AM – 5:00 PM
Saturday (open if necessary)
Sunday (open if necessary)